Appian Named a 2020 Tech100 Honoree by the Northern Virginia Technology Council

PR Newswire

MCLEAN, Va., Dec. 21, 2020 /PRNewswire/ — Appian (NASDAQ: APPN) has been named a 2020 Tech100 Honoree by the Northern Virginia Technology Council (NVTC), one of the nation’s largest technology councils with more than 500 members. The list includes groundbreaking companies, leaders and innovators within the Greater Washington region’s technology community.

“We are honored to be recognized as a Tech100 Honoree by NVTC once again. I am proud of how our employees have come together during these challenging times to support our customers and each other,” said Matt Calkins, CEO of Appian.

The NVTC Tech100 honorees were selected by a panel of independent judges and comprises 100 tech companies and 26 executives.

“While this year has presented numerous challenges to every organization and individual, it is encouraging to see so many of the area’s tech companies and executives remain resilient and committed to the health and wellbeing of their employees, the success of their companies, and industry advancement. Congratulations to Appian for being named a 2020 NVTC Tech 100 honoree and for the positive impact the firm has made in our region.” said Jennifer Taylor, NVTC president and CEO.

The Appian Low-code Automation Platform makes it easy to deliver rapid value from a new generation of powerful and scalable enterprise automation technologies, such as robotic process automation (RPA) and artificial intelligence (AI), unified on the industry’s leading platform for low-code development. In 2020, Appian launched multiple solutions to help businesses and schools get back to work safely. At the start of the pandemic, the Appian team designed, built, and launched a free Workforce Readiness application to help companies keep their employees safe from the novel coronavirus. Hundreds of companies downloaded it and shortly after, Appian launched three additional applications around COVID-19.

These applications are now being used by top companies around the world, like Garmin, Volkswagen and the University of South Florida, to keep their employees and students safe. To learn more about how we are helping to manage change during COVID-19, visit: https://www.appian.com/here-to-help/.

To learn more about Appian, go to Appian.com.

About Appian
Appian provides a low-code automation platform that accelerates the creation of high-impact business applications. Many of the world’s largest organizations use Appian applications to improve customer experience, achieve operational excellence, and simplify global risk management and compliance.

Cision View original content:http://www.prnewswire.com/news-releases/appian-named-a-2020-tech100-honoree-by-the-northern-virginia-technology-council-301196630.html

SOURCE Appian

Principle LTC’s Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention

BLAZE-2 Study of bamlanivimab in COVID-19 is currently underway, among residents and staff of skilled nursing or assisted living facilities

PR Newswire

RALEIGH, N.C., Dec. 21, 2020 /PRNewswire/ — Principle LTC’s Tower Nursing & Rehabilitation Center announced today it has partnered with Eli Lilly and Company of Indianapolis (NYSE: LLY) in a Phase 3 clinical trial evaluating bamlanivimab (LY-CoV555), alone or in combination with etesevimab (LY-CoV016). While the aim of the study overall is prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities, the study is also exploring treatment of recently diagnosed SARS-CoV-2- and COVID-positive patients who are at high-risk of developing severe disease. Early data has demonstrated that bamlanivimab can keep patients in the early stages of COVID-19 from developing more severe symptoms that require hospitalization.

Principle LTC and Tower’s continued response to the COVID-19 pandemic is focused on the safety of staff, residents, and the surrounding community. The company’s vision has never been more important than now— To be the innovators in the care we provide, the work culture we create and the partnerships we form. “The pandemic has wreaked havoc on our frail elderly in the United States and throughout the world. Our entire organization at Principle has been battling to find the newest and best methods to assist in the prevention and treatment. We are therefore proud to be working with Lilly to improve our understanding of COVID-19 and hopefully come one step closer to preventing and treating this terrible disease.” said Dr. John Lue, Jr., Corporate Medical Consultant for Principle LTC.

“COVID-19 has had a devastating impact on nursing home residents. We’re working as fast as we can to create medicines that might stop the spread of COVID-19 to these vulnerable individuals,” said Daniel Skovronsky, M.D., Ph.D., Eli Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Lilly’s study of the antibody drug is experimental, and participation by residents and staff is voluntary. In this unique trial, once certain COVID-19 positive criteria are met at the facility, Lilly will deploy a mobile research unit and implement an infusion clinic onsite. For more information, visit www.BLAZE2study.com or call 800-953-5234 to speak with a study representative.

Bamlanivimab and etesevimab are man-made antibody therapies that are being tested in multiple clinical trials for the prevention and treatment of COVID-19. These neutralizing antibodies were created from the antibodies in the blood of some of the first people to recover from COVID-19 and are specifically designed to attack SARS -CoV-2, the virus that causes COVID-19. Laboratory studies have shown that bamlanivimab and etesevimab bind with high affinity to the SARS-CoV-2 virus and neutralize its ability to infect cells and replicate.

About Principle LTC: Principle LTC has provided medical and personal care across skilled nursing facilities and assisted living facilities to thousands of residents and patients who are unable to manage independently in NC, KY, and VA.

Cision View original content:http://www.prnewswire.com/news-releases/principle-ltcs-tower-nursing–rehabilitation-center-joins-with-eli-lilly-and-company-on-phase-3-drug-trial-for-covid-19-prevention-301196424.html

SOURCE Principle LTC (Tower Nursing & Rehabilitation Center)

Doritos Unveils New 3D Crunch, Entering a New Era of Three-Dimensional Snacking

Original “Doritos Girl” Ali Landry Returns to Help Usher in the Next Generation Version of the Fan-Favorite Snack

PR Newswire

PLANO, Texas, Dec. 21, 2020 /PRNewswire/ — After years of clamoring on social media, popular petitions, and celebrity endorsements, one of the most sought-after snacks in Frito-Lay history is making a triumphant return — updated for a new generation. Today, Doritos announced Doritos 3D Crunch, another level version of the original Doritos 3D’s introduced in the late 1990s to immense fanfare. Doritos is ushering back the same great product and iconic three-dimensional shape, but with even more bold and spicy flavor – just in time to bring some much-needed multi-dimensional joy to the Holiday season and New Year.

Since launching in 1998, Doritos 3D’s became an instant fan favorite — catapulted into the spotlight by the memorable “Laundromat” Super Bowl commercial featuring actress Ali Landry. Deemed the original “Doritos Girl,” Landry helped bring the new three-dimensional shape and flavor to households across the country — making Doritos 3D’s one of the brand’s most successful product innovations. Phased-out in the early 2000s, fans from coast-to-coast have been clamoring to bring back Doritos 3D’s ever since. Landry will be announcing the new product today on her social channels.

In celebration of Doritos 3D Crunch, the brand is taking the original and turning it up a notch. With the same three-dimensional shape, new Doritos 3D Crunch will be available in two bold flavors: Spicy Ranch and Chili Cheese Nacho. These flavor offerings are Frito-Lay’s latest expansion in the hot-and-spicy food category, one of the fastest-growing segments in the food industry.

“Doritos 3D Crunch is one of our most anticipated product launches ever. What’s exciting is that we didn’t just bring back the original — we’ve evolved it to reflect the snacking trends of a new generation,” said Rachel Ferdinando, SVP and CMO, Frito-Lay North America. “We’re thrilled to introduce a new version at a time when we all could use a small moment of joy.”

To help fans reimagine snacking on Doritos 3D Crunch — something Millennials will remember and Gen Z will love — the brand is once again partnering with Landry to launch a nationwide challenge. Paying homage to the original “Laundromat” commercial, Landry will ask fans to catch Doritos 3D in their mouth in the boldest ways possible. Fans are encouraged to check out the #Doritos3DChallenge on TikTok starting December 28.

Doritos 3D Spicy Ranch and Doritos 3D Chili Cheese Nacho are in stores starting Monday, December 28 in 6 oz. bags for a suggested retail price of $4.29 and 2 oz. bags for $1.89. For more information, please visit Doritos.com.

About Doritos

Doritos believes there’s boldness in everyone. We champion those who are true to themselves, who live life fully engaged and take bold action by stepping outside of their comfort zone and pushing the limits. Doritos is one of many Frito-Lay North America brands – the $17 billion convenient foods division of PepsiCo, Inc. (NASDAQ: PEP), which is headquartered in Purchase, NY. Learn more about Frito-Lay at the corporate website, http://www.fritolay.com/, and on Twitter http://www.twitter.com/fritolay.

About PepsiCo

PepsiCo products are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world. PepsiCo generated more than $64 billion in net revenue in 2018, driven by a complementary food and beverage portfolio that includes Frito-Lay, Gatorade, Pepsi-Cola, Quaker and Tropicana. PepsiCo’s product portfolio includes a wide range of enjoyable foods and beverages, including 22 brands that generate more than $1 billion each in estimated annual retail sales. Guiding PepsiCo is our vision to Be the Global Leader in Convenient Foods and Beverages by Winning with Purpose. “Winning with Purpose” reflects our ambition to win sustainably in the marketplace and embed purpose into all aspects of the business. For more information, visit www.pepsico.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/doritos-unveils-new-3d-crunch-entering-a-new-era-of-three-dimensional-snacking-301196346.html

SOURCE Frito-Lay

Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

PR Newswire

SAN DIEGO, Dec. 21, 2020 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

Evofem’s CEO, Saundra  Pelletier, will provide updates on the commercialization of Phexxi® (lactic acid, citric acid and potassium bitartrate), the first and only FDA-approved, hormone free contraceptive vaginal gel, and the pivotal Phase 3 EVOGUARD trial, which is evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and currently enrolling subjects at study centers across the U.S. 

The presentation will be available for on-demand listening  beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the Investors section of the Evofem Biosciences website at www.evofem.com, under the Events and Presentations tab.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company’s first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, ‘EVOGUARD,’ for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf

Evofem Biosciences, Inc.
[email protected]
Mobile: (917) 673-5775

Media Contact

Ellen Thomas

Evofem Biosciences, Inc.
[email protected]
Mobile: (718) 490-3248

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-the-hc-wainwright-bioconnect-2021-virtual-conference-301196515.html

SOURCE Evofem Biosciences, Inc.

US Navy Awards L3Harris Technologies $496 Million Next Generation Jammer Low Band Tactical Jamming System Contract

US Navy Awards L3Harris Technologies $496 Million Next Generation Jammer Low Band Tactical Jamming System Contract

Highlights:

  • Next Generation Jammer Low Band replaces the 50-year-old jammer in the lower frequency range
  • Provides 360° field of regard for defeating multi-directional threats
  • Software-defined system enables rapid, in theater, technology insertion

SALT LAKE CITY–(BUSINESS WIRE)–
The U.S. Navy has awarded L3Harris Technologies (NYSE:LHX) a five-year, $496 million contract to deliver prototype tactical jamming pods designed to extend U.S. Air superiority.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005439/en/

The Next Generation Jammer Low Band (NGJ-LB) is a high-powered, high-capacity airborne electronic warfare (EW) system. (Photo: Business Wire)

The Next Generation Jammer Low Band (NGJ-LB) is a high-powered, high-capacity airborne electronic warfare (EW) system. (Photo: Business Wire)

The Next Generation Jammer Low Band (NGJ-LB) is a high-powered, high-capacity airborne electronic warfare (EW) system. L3Harris’ single-pod solution enables extended stand-off jamming capability, covers a broad spectrum and processes an increased number of threats. The system operates seamlessly with joint and allied forces, and provides growth capacity for emerging threats.

“The Next-Generation Jammer Low Band contract highlights L3Harris’ long-standing commitment to support the U.S. Navy’s mission to maintain superiority on land, sea and in the air,” said Dana Mehnert, President, Communication Systems Segment, L3Harris. “The selection of L3Harris demonstrates our company’s strength as a technology prime to provide a truly unique solution that meets the Navy’s need to address all contested environments.”

The company will deliver eight operational pods to NAVAIR for fleet assessment, and additional test assets for airworthiness and design verification. The NGJ-LB pods will be flown on the EA-18G Growler and continue the Navy’s plan to address operational gaps and replace the aging ALQ-99 Tactical Jamming System pods operating in the low frequency spectrum.

About L3Harris Technologies

L3Harris Technologies is an agile global aerospace and defense technology innovator, delivering end-to-end solutions that meet customers’ mission-critical needs. The company provides advanced defense and commercial technologies across air, land, sea, space and cyber domains. L3Harris has approximately $18 billion in annual revenue and 48,000 employees, with customers in more than 100 countries. L3Harris.com.

Forward-Looking Statements

This press release contains forward-looking statements that reflect management’s current expectations, assumptions and estimates of future performance and economic conditions. Such statements are made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The company cautions investors that any forward-looking statements are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements. Statements about the value or expected value of orders, contracts or programs and about our system capabilities are forward-looking and involve risks and uncertainties. L3Harris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Jennifer Bolton

Communications Systems

[email protected]

801-209-2153

Jim Burke

Media Relations

[email protected]

321-727-9131

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Mobile/Wireless Technology Contracts Security Air Transport Aerospace Software Manufacturing Defense

MEDIA:

Logo
Logo
Photo
Photo
The Next Generation Jammer Low Band (NGJ-LB) is a high-powered, high-capacity airborne electronic warfare (EW) system. (Photo: Business Wire)

Apple Hospitality REIT Enhances Corporate Responsibility Disclosures

Apple Hospitality REIT Enhances Corporate Responsibility Disclosures

RICHMOND, Va.–(BUSINESS WIRE)–
Apple Hospitality REIT, Inc. (NYSE:APLE) (the “Company” or “Apple Hospitality”) today announced that it has published enhanced disclosures related to the Company’s ongoing commitment to the environment, social responsibility and corporate governance.

“Apple Hospitality has always worked to uphold high environmental, social and governance standards, and we are pleased to provide additional detail regarding our ongoing efforts in these areas,” commented Justin Knight, Chief Executive Officer of Apple Hospitality. “We are committed to minimizing the environmental impact of our Company and the hotels that we own and are dedicated to making a positive impact throughout our Company, the hotel industry, our local communities and the many communities our hotels serve. We remain committed to racial and gender equality and the goal of a world free of all forms of discrimination. Together with our brand affiliates, the management teams at our hotels and other industry colleagues, we are focused on advancing sustainability initiatives that effectively balance environmental stewardship with our business goals, improving our communities through thoughtful outreach programs, and promoting diversity and inclusion. These initiatives have always been incredibly important to us, and we will to continue to enhance our programs and related disclosures.”

Apple Hospitality’s enhanced disclosures are intended to provide stakeholders with a better understanding of the Company’s policies, programs, procedures and initiatives related to environmental stewardship, social responsibility and corporate governance and are available within the Corporate Responsibility section of the Company’s website at applehospitalityreit.com/corporate-responsibility. The Company anticipates it will continue to enhance disclosures related to these issues over time.

About Apple Hospitality REIT, Inc.

Apple Hospitality REIT, Inc. (NYSE:APLE) is a publicly traded real estate investment trust (“REIT”) that owns one of the largest and most diverse portfolios of upscale, rooms-focused hotels in the United States. Apple Hospitality’s portfolio consists of 235 hotels with more than 30,000 guest rooms located in 87 markets throughout 34 states. Concentrated with industry-leading brands, the Company’s portfolio consists of 104 Marriott-branded hotels, 126 Hilton-branded hotels, three Hyatt-branded hotels and two independent hotels. For more information, please visit www.applehospitalityreit.com.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are typically identified by use of statements that include phrases such as “may,” “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “target,” “goal,” “plan,” “should,” “will,” “predict,” “potential,” “outlook,” “strategy,” and similar expressions that convey the uncertainty of future events or outcomes. Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.

Currently, one of the most significant factors that could cause actual outcomes to differ materially from the Company’s forward-looking statements is the adverse effect of COVID-19, including possible resurgences, on the Company’s business, financial performance and condition, operating results and cash flows, the real estate market and the hospitality industry specifically, and the global economy and financial markets generally. The significance, extent and duration of the impacts caused by the COVID-19 outbreak on the Company will depend on future developments, which are highly uncertain and cannot be predicted with confidence at this time, including the scope, severity and duration of the pandemic, the extent and effectiveness of the actions taken to contain the pandemic or mitigate its impact, the potential for additional hotel closures/consolidations that may be mandated or advisable, whether based on increased COVID-19 cases or other factors, the slowing or potential rollback of “reopenings” in certain states, and the direct and indirect economic effects of the pandemic and containment measures, among others. Moreover, investors are cautioned to interpret many of the risks identified under the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as being heightened as a result of the ongoing and numerous adverse impacts of COVID-19. Such additional factors include, but are not limited to, the ability of the Company to effectively acquire and dispose of properties; the ability of the Company to successfully integrate pending transactions and implement its operating strategy; changes in general political, economic and competitive conditions and specific market conditions; reduced business and leisure travel due to travel-related health concerns, including the widespread outbreak of COVID-19 or an increase in COVID-19 cases or any other infectious or contagious diseases in the U.S. or abroad; adverse changes in the real estate and real estate capital markets; financing risks; litigation risks; regulatory proceedings or inquiries; and changes in laws or regulations or interpretations of current laws and regulations that impact the Company’s business, assets or classification as a REIT. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore there can be no assurance that such statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the results or conditions described in such statements or the objectives and plans of the Company will be achieved. In addition, the Company’s qualification as a REIT involves the application of highly technical and complex provisions of the Internal Revenue Code. Readers should carefully review the risk factors described in the Company’s filings with the Securities and Exchange Commission, including but not limited to those discussed in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. Any forward-looking statement that the Company makes speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements or cautionary factors, as a result of new information, future events, or otherwise, except as required by law.

For additional information or to receive press releases by email, visit www.applehospitalityreit.com.

Apple Hospitality REIT, Inc.

Kelly Clarke, Vice President, Investor Relations

804-727-6321

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Other Philanthropy Commercial Building & Real Estate Construction & Property Environment Lodging Travel Philanthropy REIT

MEDIA:

Logo
Logo

Teradata Appoints Todd Cione as Chief Revenue Officer

Teradata Appoints Todd Cione as Chief Revenue Officer

Experienced Global Sales Leader with Proven Record Growing Revenue and Executing Cloud Transformations

SAN DIEGO–(BUSINESS WIRE)–Teradata (NYSE: TDC), the cloud data analytics platform company, today announced the appointment of Todd Cione as Chief Revenue Officer, effective January 4, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005228/en/

Todd Cione, Teradata CRO (Photo: Business Wire)

Todd Cione, Teradata CRO (Photo: Business Wire)

Cione brings to Teradata more than 25 years of experience in global sales, marketing, channel and operations at large multi-national technology organizations, including most recently at Apple, and previously with Oracle, Rackspace and Microsoft. He is a results-oriented executive with a proven track record of delivering predictable and profitable growth, and has successfully led organizations through cloud-based transformations. Cione will report to Steve McMillan, President and CEO of Teradata.

“I am pleased to welcome Todd to the Teradata team and look forward to working closely with him as we advance our go-to-market initiatives and deliver consistent, profitable revenue growth,” said McMillan. “We have been successfully executing on our cloud-first strategy, which has deeply resonated with our customers globally. We are confident that Todd’s experience and diverse skill set will be invaluable in helping customers unlock value from their data.”

“I am excited about joining Teradata and helping to accelerate its cloud-first momentum. I deeply share Teradata’s customer-centric purpose and look forward to delivering exceptional customer experiences with our cloud-based data analytics platform,” said Cione. “Working closely with Steve and the rest of the Company’s talented team, we will continue to help our customers harness the power of data and provide sustainable value for our shareholders. I look forward to hitting the ground running to drive sales strategies that strengthen our market position and continue to drive top-line growth.”

About Todd Cione

Cione most recently served as Head of U.S. Enterprise Accounts at Apple Inc., a role he held since 2017, where he was responsible for overseeing large enterprise customers and was a key contributor to driving customer success. Previously, he was SVP of Oracle’s Digital, North America Applications, and also served as Chief Revenue Officer of Rackspace. Additionally, Cione spent 15 years at Microsoft, where he held roles of increasing responsibility in the U.S. and Asia, including General Manager, Asia Pacific Region Marketing & Operations, a market with over $4 billion in revenue, and General Manager and Managing Director, Asia Pacific Region Enterprise & Services Sales. During his tenure at Microsoft, Cione was an integral contributor to the Company’s transition to the cloud and helped launch Azure and Office 365 in U.S. and Asian markets.

Cione has a BA in English and Business from Baylor University with continuing executive education at INSEAD’s Asian International Executive Program and the University of Nebraska-Lincoln’s Gallup Leadership Development Program.

About Teradata

Teradata is the cloud data analytics platform company, built for a hybrid multi-cloud reality, solving the world’s most complex data challenges at scale. We help businesses unlock value by turning data into their greatest asset. See how at Teradata.com.

The Teradata logo is a trademark, and Teradata is a registered trademark of Teradata Corporation and/or its affiliates in the U.S. and worldwide.

MEDIA CONTACT

Jennifer Donahue

858-485-3029 office

[email protected]

INVESTOR CONTACT

Christopher T. Lee

858-485-2523 office

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Technology Other Technology Telecommunications Software Networks Internet

MEDIA:

Photo
Photo
Todd Cione, Teradata CRO (Photo: Business Wire)

ZoomInfo Awarded Three Honors for 2020 Company Culture Excellence by Comparably

ZoomInfo Awarded Three Honors for 2020 Company Culture Excellence by Comparably

Accolades Include Best Company Culture, Best CEO, and Best Companies for Women

VANCOUVER, Wash.–(BUSINESS WIRE)–ZoomInfo (NASDAQ: ZI), a global leader in go-to-market intelligence solutions, today announced it has won three more Comparably Awards for company culture excellence in 2020.

In considering 60,000 companies for its Best Places to Work Awards, Comparably placed ZoomInfo at No. 15 on its large companies list for Best Company Culture. The outlet also ranked ZoomInfo Founder and CEO Henry Schuck in the top-20 on its list of Best CEOs at large companies. Additionally, ZoomInfo was included on the large companies list of the Best Companies for Women.

“I am immensely proud that our company has been recognized as one of the best places to work and one that places a high priority on diversity and inclusion,” said Schuck. “At ZoomInfo, we are building a unique workplace culture that engages, challenges, and rewards our team, and we all are excited about where we’re headed as a company. Our team members continue to better both themselves and our company despite the unprecedented challenges of 2020.”

Earlier this year, Comparably named ZoomInfo to its 2020 lists of large companies for Happiest Employees, Best Compensation, and Best Perks & Benefits.

A workplace culture and compensation monitoring site, Comparably evaluates companies based on sentiment ratings anonymously provided by employees about their workplaces in multiple categories on Comparably.com during a 12-month period (Dec. 1, 2019 – Dec. 1, 2020).

“The attributes that define excellent workplaces and leaders have not changed this year,” said Comparably CEO Jason Nazar. “The best CEOs and companies invest just as much in the growth of the business as they do in their employees. ZoomInfo’s multiple award wins this year are a testament to Henry Schuck’s strong mission-driven leadership, and the company’s commitment to transparency and diversity.”

To view the complete list of Comparably Award winners, please visit www.comparably.com/awards. To learn more about career opportunities at ZoomInfo, please visit www.zoominfo.com/about/careers.

About Comparably

Comparably is a leading workplace culture and compensation monitoring site that provides the most comprehensive and accurate representation of what it’s like to work at companies. Employees can anonymously rate their employers in 20 different workplace culture categories, providing the public a transparent and in-depth look at the experiences workers have based on their gender, ethnicity, age, department, experience, location, education, and company size. Since launching in 2016, Comparably has accumulated 10 million ratings across 60,000 U.S. companies. The platform has become one of the fastest-growing SaaS solutions for employer branding and trusted third-party site for workplace and salary data, including its annual Best Places to Work series.

About ZoomInfo

ZoomInfo (NASDAQ: ZI) is a Go-To-Market Intelligence Solution for more than 15,000 companies worldwide. The ZoomInfo platform empowers business-to-business sales, marketing, and recruiting professionals to hit their number by pairing best-in-class technology with unrivaled data coverage, accuracy, and depth of contacts. With integrations embedded into workflows and technology stacks, including the leading CRM, Sales Engagement, Marketing Automation, and Talent Management applications, ZoomInfo drives more predictable, accelerated, and sustainable growth for its customers. ZoomInfo emphasizes GDPR and CCPA compliance. In addition to creating the industry’s first proactive notice program, the company is a registered data broker with the states of California and Vermont. Read about ZoomInfo’s commitment to compliance, privacy, and security. For more information about our leading Go-To-Market Intelligence Solution, and how it helps sales, marketing, and recruiting professionals, please visit www.zoominfo.com.

Media

Rob Morse

Manager, Communications

ZoomInfo

541-556-9387

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Software Professional Services Search Engine Marketing Data Management Consumer Technology Small Business Marketing Women Advertising Human Resources Communications

MEDIA:

Logo
Logo

AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico

AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico

Study will provide real-world data to evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population

VANCOUVER, British Columbia–(BUSINESS WIRE)–
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly’s trial, in collaboration with the state of New Mexico and major local institutions, will collect data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. As part of this study, Lilly will employ its unique mobile research units used successfully in other studies. Additional details regarding the new trial can be found here.

“By deploying on-site infusion clinics, Lilly continues to lead in finding ways to bring antibody treatments to patients,” said Carl Hansen, Ph.D., CEO of AbCellera. “We applaud their continued innovation and tireless efforts in fighting the COVID-19 pandemic.”

Bamlanivimab is currently authorized in the United States and Canada for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. Both the Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration and the interim authorization granted by Health Canada under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 are based on data from BLAZE-1, a randomized, double-blind placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Data from BLAZE-1 showed bamlanivimab reduced viral load, symptoms, and hospitalizations.

AbCellera’s COVID-19 response was based on capabilities developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of P3 is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.

About Bamlanivimab

Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing, testing bamlanivimab alone and in combination with a second antibody. Data from the monotherapy arms of BLAZE-1 were published in the New England Journal of Medicine. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

Media:

Jessica Yingling, Ph.D.

+1 (236) 521-6774

[email protected]

Investor Relations:

[email protected]

Business Development:

Kevin Heyries, Ph.D.

+1 (604) 559.9005

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Research Infectious Diseases Clinical Trials Biotechnology Health Pharmaceutical General Health Other Science Science

MEDIA:

Logo
Logo

Amazfit Bip U Series and Amazfit Smart Scale Available Just in Time for the Holidays

Amazfit Bip U Series and Amazfit Smart Scale Available Just in Time for the Holidays

The Amazfit Bip U and Amazfit Bip U Pro offer all-around health & fitness tracking; the Amazfit Smart Scale offers comprehensive health metrics

IRVINE, Calif.–(BUSINESS WIRE)–
Amazfit has released its latest addition to the Amazfit Bip series of smartwatches, the Amazfit Bip U ($59.99) and Amazfit Bip U Pro ($69.99), and expanded its smart technology offering with the Amazfit Smart Scale ($49.99). All three products were designed to embody Amazfit’s commitment to connect health with technology–making life easier, more efficient and fun. For a limited time, U.S. customers can purchase these products on sale for holiday gifting at us.amazfit.com and Amazon.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005123/en/

Amazfit Bip U Series and Amazfit Smart Scale (Graphic: Business Wire)

Amazfit Bip U Series and Amazfit Smart Scale (Graphic: Business Wire)

Amazfit Bip U Series – Dynamic features for an active lifestyle

These lightweight and attractive smartwatches are designed to deliver the very latest in health and fitness tracking at an affordable price. The Amazfit Bip U Series is packed with technology that will keep you in touch with your activity level, give you the must-have details about your health metrics and can be customized to your personal style.

  • Design and Display – An upgraded color 1.43” HD display delivers clear images and is your portal to an incredible array of features including more than 50 watch faces[1] to match your style. With 2.5D glass, anti-fingerprint coating and 320×302 pixel resolution, all your messages and notifications are easy to read. Weighing just 31g, this smartwatch is designed for all-day comfort. When the Amazfit Bip U Series is fully charged it can provide up to nine days[2] of health and fitness tracking.
  • Fitness Tracking – The Amazfit Bip U Series provides all the exercise data you need on your wrist. Choose from more than 60 professional sports modes[3] including running, cycling, yoga, dancing, skating, kickboxing and more. During workouts the Amazfit Bip U Pro has a high-precision built-in GPS[4], while the Amazfit Bip U can connect to your phone’s GPS for positional tracking. Both also feature 5 ATM Water-Resistance[5].
  • Health Metrics and Monitoring[6]– All-around health and fitness tracking includes blood-oxygen level measurement, along with heart rate, sleep quality and stress level monitoring. The Amazfit Bip U Series can even help track menstrual cycles and ovulation to provide useful reminders and information.
  • Lifestyle Companion – The Amazfit Bip U Series can sync with your smartphone for notifications, including text messages, emails and popular apps. It also gives you a wealth of helpful information right on your wrist, including alarms, weather forecasts, a Bluetooth music controller for your phone, a remote control for your camera and more.
  • Amazon Alexa[7]The Amazfit Bip U Pro supports Amazon Alexa–ask questions, get translations, set alarms and timers, check the weather and control your smart home devices at the lift of your wrist.

Amazfit Smart Scale – Comprehensive health data at your feet

The Amazfit Smart Scale comes in a stunning gradient Aurora design and features a 3.4” LCD display to access up to eight of the most important body health metrics at a glance. Through the companion app, users can pick their favorite data to be displayed on the screen from the pre-set selection of body health metrics.

  • High-Accuracy Weight Measurement– The high-precision G-shaped sensor is sensitive enough to detect minor weight changes of up to 0.1lbs[8]. This means the Smart Scale can show the change in your weight even if you only drink a cup of water.
  • 16 Body Health Metrics – With its high-performance data processing chip, the Smart Scale provides metrics for 16 body health indicators based on the basic information you enter, which helps you easily understand your overall physical condition. Metrics include body weight, body fat rate, muscle mass, body water percentage, body mass index (BMI) and more. It can measure health data in either normal or sport mode to provide more accurate measurements for a wider range of users.
  • Dual Data Connection – The Amazfit Smart Scale supports both Wi-Fi and Bluetooth connections. All health data measured is synchronized more conveniently and efficiently to your mobile phone and in the cloud for you to check anytime, anywhere.
  • Multi-Account Management – The Amazfit Smart Scale supports up to 10 accounts, each of which can be used by up to 12 family members. The scale has smart user recognition to identify family members sharing the same account to more easily facilitate daily use[9]. It also provides a guest mode and erases guest data later.

Holiday Deals on Amazfit Products

Last minute holiday shoppers can enjoy Amazfit’s holiday deals through the New Year. Customers can score discounts of up to $40 off and free standard shipping on their favorite Amazfit products via us.amazfit.com and Amazon:

  • Holiday Deals until December 24, 2020

    • Amazfit Smart Scale for $44.99 (reg. $49.99)
    • Amazfit T-Rex for $119.99 (reg. $139.99)
    • Amazfit Bip S for $59.99 (reg. $69.99)
    • Amazfit GTS for $109.99 (reg. $149.99)
    • Amazfit Band 5 for $39.99 (reg. $49.99)
    • Amazfit PowerBuds for $79.00 (reg. $99.00)
  • Holiday Deals until December 26, 2020

    • Amazfit Bip U for $49.99 (reg. $59.99)
    • Amazfit GTS 2 for $159.99 (reg. $179.99)
    • Amazfit GTR 2 for $159.99 (reg. $179.99)
  • Holiday Deals until January 2, 2021

    • Amazfit GTR 42mm for $99.99 (reg. $129.99)

About Amazfit

Established in September 2015, Amazfit is a private brand owned by Huami Technology (NYSE: HMI), offering seven series of smartwatch and bracelets products including the Stratos series, Basic series, Flagship series, Health series, Fashion series, Outdoor series, and X series. Amazfit also provides other smart hardware related to sports and health, including TWS sports earbuds, smart treadmills, smart body fat scales and sports gear. With outstanding design and craftsmanship, Amazfit smartwatch products have won many prizes, such as the German iF Industrial Design Award and the Red Dot Design Award. Currently, Amazfit products hit the markets of more than 70 countries and regions, including the United States, Germany, and Japan. According to an IDC global wearable device market tracking report, in the first half of 2020, Amazfit watches claimed the largest share of the adult watch market in Italy, Spain, India and other regions, and were also among the top products in regions such as China, Germany, France, Russia, and Brazil.

To find more details about us visit: https://us.amazfit.com/

Huami Technology, operating since 2013, is a cloud-based healthcare service provider offering the world’s leading smart wearable technologies. In February 2018, Huami Technology was listed on the New York Stock Exchange (NYSE) (stock code: HMI).

[1] Four built-in watch faces. You can replace two of the built-in watch faces from a selection of 40+ online watch faces in the Zepp App.

[2] Test conditions: the device is fully charged, the automatic heart rate measurement feature is enabled for 10 minutes, the Activate on Raise feature is enabled, and other settings are kept in default states. Each day involves the following operations: 50 notifications are received and displayed, 200 screen activations on raise are conducted, outdoor running every other day for 30 minutes and SpO2 measurement twice per day. During actual use, battery life is related to various factors such as settings, operations, and operating conditions, and therefore may differ from laboratory data.

[3] 60+ sports modes include: Ballet, belly dance, square dance, street dance, ballroom dance, dance, zumba, outdoor running, treadmill, walking, outdoor cycling, indoor cycling, BMX, core training, rowing machine, mixed aerobics, strength training, stretching, stair-climbing machine, Pilates, flexibility training, indoor fitness, stair stepper, step training, gymnastics, elliptical, yoga, free training, hunting, fishing, roller skating, sailing, skateboarding, pool swimming, open water swimming (Amazfit Bip U Pro only), curling, outdoor skating, indoor skating, cricket, baseball, bowling, squash, basketball, softball, gateball, volleyball, table tennis, handball, badminton, fencing, karate, boxing, judo, wrestling, tai chi, muay thai, taekwondo, martial arts, kickboxing, archery, equestrianism, jumping rope.

[4] Only Amazfit Bip U Pro has built-in GPS; Amazfit Bip U supports connection with mobile phone GPS.

[5] Based on the ISO 22810:2010 standard, the watch delivers a water resistance level of up to 50 meters and has passed the test conducted by the BUREAU VERITAS CONSUMER PRODUCTS SERVICES. The report number is XRX-ESH-P20062078.

[6] This product is not a medical device. All the measurement data and results are provided for reference only and cannot be used to perform professional diagnosis or monitoring of any medical conditions. Due to external factors (such as arm hair, tattoos, or darker skin), there may be cases where measurement results are inaccurate or even unavailable. To measure SpO2, please keep your arm still.

[7] Built-in Alexa is supported only on the Amazfit Bip U Pro. Alexa is not available in all countries/regions. To see the countries/regions available, languages supported, as well as how to activate and use Alexa on the Amazfit Bip U Pro, please visit support.amazfit.com.

[8] Minimal change 0.1lbs (11-220lbs), 0.2lbs (0.2-0.4lbs). Due to the influence of temperature difference and time difference on the sensor, the weighing accuracy can sometimes vary and not reach 0.1lbs. The maximum tolerance margin is 0.2lbs.

[9] When the weight difference of family members exceeds 6.6lbs, the user can be automatically identified. When the weight difference of family members is less than 6.6lbs, the users’ names with the same weight will be displayed on the display screen, so users can select the correct one.

Ivan Wang

Marketing Director, North America

[email protected]

Stacy Lee

PR Manager, North America

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Retail Health Consumer Other Health Other Retail Software General Health Other Consumer Hardware Fitness & Nutrition Data Management Consumer Electronics

MEDIA:

Photo
Photo
Amazfit Bip U Series and Amazfit Smart Scale (Graphic: Business Wire)
Logo
Logo